Zacks Investment Research lowered shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a buy rating to a hold rating in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Guggenheim began coverage on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a research report on Wednesday, November 27th. They set a buy rating on the stock.

Shares of MOR opened at $33.04 on Friday. The firm’s 50-day moving average is $34.81 and its two-hundred day moving average is $29.99. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a twelve month low of $22.46 and a twelve month high of $37.96.

Recommended Story: VIX – Volatility Index

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.